Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06219720 · ClinicalTrials.gov registry record
The Texas Interprofessional Pharmacogenomics (IPGx)
A clinical trial of Adverse Drug Reaction, sponsored by Texas A&M University.
- Recruiting
- Registry status
- 50
- Enrollment target
- 1
- Study location
NCT06219720: Recruiting study of Adverse Drug Reaction, sponsored by Texas A&M University.
NCT06219720 is a study of Adverse Drug Reaction that is actively recruiting participants, run by Texas A&M University. The registered enrollment target is 50 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06219720, a study of Adverse Drug Reaction, is actively recruiting participants, sponsored by Texas A&M University.
- RECRUITING
- Registry status
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigator's primary aim is to evaluate polypharmacy-associated adverse drug reactions (ADR) in a pilot study of at-risk patients using state-of-the-art pharmacogenomic technology and to use this information to make recommendations for optimization of pharmacotherapy regimens. The data from the pilot cohort will be used to optimize and integrate a customized electronic decision support (clinical semantic network; CSN) dashboard to identify drug regimens that should be modified, replaced, or discontinued. A secondary objective of the pilot study is to evaluate the capacity/saturation of CYP P450 enzymatic pathways in polypharmacy patients. A third objective is to determine the feasibility of the planned informatics workflows between the CLIA lab, the EMR, and the Family Medicine Practice.
Primary Outcome
Patients will be referred to the Texas A\&M Interprofessional Pharmacogenomics Clinic (IPGx) by their primary care physicians. A physician or ambulatory pharmacist in the IPGx clinic or Family Care Clinic will obtain a complete medical history, physical examination, and validate the patient's current concomitant medication list at the IPGx during the office visit. Patient medical information would be input into the CSN, which functions as a computable EHR medical record analysis, evaluation of p
Conditions Studied
Study Locations (1)
Texas
- The Interprofessional Pharmacogenomics (IPGx) Clinic - Bryan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2021-12-15 |
| Est. Completion | 2027-11 |
What NCT06219720 shows while recruiting
NCT06219720 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 50 participants, a relatively small participant target.
The record links to 1 condition, with Adverse Drug Reaction appearing as the primary indexed condition, and to 0 interventions.
NCT06219720 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06219720 about?
NCT06219720 is a clinical study titled "The Texas Interprofessional Pharmacogenomics (IPGx)". The investigator's primary aim is to evaluate polypharmacy-associated adverse drug reactions (ADR) in a pilot study of at-risk patients using state-of-the-art pharmacogenomic technology and to use this information to make recommendations for optimization of pharmacotherapy regimens. The data from th...
What is the current status of trial NCT06219720?
This trial is currently recruiting. The enrollment target is 50 participants. The study started on 2021-12-15. Estimated completion is 2027-11.
What conditions does trial NCT06219720 study?
This clinical trial studies the following conditions: Adverse Drug Reaction.
Who is sponsoring clinical trial NCT06219720?
This trial is sponsored by Texas A&M University, which has 95 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06219720 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Adverse Drug Reaction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI